The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Advanced Hepatitis C Infection: Six Tips to Temper Cirrhosis

Back to News Homepage

Next

Modern and Traditional Research Expands Knowledge of Liver Disease

Infergen and Ribavirin Trial Brings Renewed Hope to Previous Non-Responders

June 22, 2009

Print this page

Although their first attempt at Hepatitis C antiviral therapy was unsuccessful, a significant number of previous non-responders achieved a sustained viral response with once-daily Infergen with Ribavirin.

Three Rivers Presents Positive Results For Phase-III Hepatitis C Trial

16-June-2009
By Staff Reporter

Phase-III direct trial of once-daily Infergen with Ribavirin in Hepatitis C virus treatment failures.

Pennsylvania-based Three Rivers Pharmaceuticals has announced positive results from phase-III direct trial of once-daily Infergen with Ribavirin in Hepatitis C virus treatment failures.

Among participants who failed initial treatment with PEG-IFN/RBV, retreatment with Infergen in combination with RBV, yielded sustained virological response rates (as high as 31.6%) in interferon-sensitive patients with low baseline liver fibrosis scores. Overall intent to treat analysis was 6.9% among the 9 mcg/day group and 10.7% in the 15 mcg/day group.

Direct trial, a phase III, randomized, open-label, multicenter, US-based trial was conducted to investigate the efficacy, tolerability, and safety of daily Infergen at dosages of 9 and 15 mcg/day, administered with daily weight-based RBV.

Patients with cirrhosis were less likely to benefit from retreatment with Infergen and RBV, unless they displayed previous interferon sensitivity of at least 1-log drop in viral levels on prior therapy.

Donald Kerrish, President and CEO of Three Rivers Pharmaceuticals, said: “These results represent a significant step forward for HCV patients who deserve a second chance at a potential cure for this chronic viral infection.”

URL for Article Source: http://www.pharmaceutical-business-review.com/news/three_rivers_presents_positive_results_for_phaseiii_hepatitis_c_trial_090616

No Comments - be the first!
Share
Share

Previous

Advanced Hepatitis C Infection: Six Tips to Temper Cirrhosis

Back to News Homepage

Next

Modern and Traditional Research Expands Knowledge of Liver Disease

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.